Dual Orexin Receptor Antagonists (DORAs) are a class of prescription medications that promote sleep by selectively blocking orexin, a key neuropeptide that signals wakefulness. Unlike traditional hypnotics which cause broad sedation, DORAs are thought to facilitate a more naturalistic sleep architecture by 'turning down' the brain's wake systems. From a healthspan perspective, achieving consistent, high-quality sleep is critical for glymphatic clearance of neurotoxins, hormonal regulation, and cellular repair processes.
Verdict
A promising, targeted tool for restoring sleep architecture, requiring medical guidance.
HEALTHSPAN IMPACT
High Value
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$350 - $550
Protocol
- Taken 30 minutes before bedtime as needed to improve sleep onset and maintenance.
- Dosages are titrated to the lowest effective dose to minimize next-day somnolence.
Flags
- Requires a prescription and medical supervision.
- Risk of next-day somnolence can impair driving or operating heavy machinery.
- May worsen depression or suicidal ideation in susceptible individuals.
- Contraindicated in patients with narcolepsy.
- Potential for complex sleep behaviors like sleepwalking or sleep-driving.
- Avoid co-administration with strong CYP3A inhibitors which can increase drug concentration.